Kornimate/medical-research-clean huggingface dataset:
probiotics for gout / hyperuricemia: a randomized, intervention, parallel controlled, multicenter clinical trial

Conditions: Gout; Hyperuricemia

Summary: under the premise of double-blind and non-interference clinical treatment, to evaluate the clinical efficacy and safety of probiotic lactobacillus zhang combined with routine treatment for gout hyperuricemia.


Eligibility criteria:
inclusion criteria: subjects are eligible for inclusion in this study only if they meet all of the following criteria 1. 18-70 years old, gender unlimited ； 2. previous history of gout ； 3. according to the criteria of gout classification and diagnosis of eular / acr in 2015； 4. fasting serum uric acid ≥ 480 μ mol / l (8mg / dl) exclusion criteria: if the subjects meet any of the following criteria, they will not be selected ： 1. gout in the past two weeks ； 2. secondary hyperuricemia ； 3. patients with abnormal liver and kidney function (alt, ast are 1.5 times higher than the normal value, cr is 1.5 times higher than the upper limit of the normal value； 4. wbc \< 4.0 × 109 / l, plt \< 100 × 109 / l, hgb \< 90g / l, or other hematological diseases ； 5. bad blood pressure control (bp\>160mmhg/100 mmhg) 6. type i diabetes or poorly controlled type ii diabetes: fasting blood glucose ≥ 8.5mmol/l ； 7. patients with active peptic ulcer ； 8. patients with gastrointestinal cancer ； 9. patients with previous intestinal diseases such as lactose intolerance, irritable bowel syndrome, inflammatory bowel disease and habitual diarrhea ； 10. use of drugs that affect the metabolism or excretion of uric acid and cannot / cannot be stopped, including azathioprine, 6-mercaptopterin, thiazide diuretics, aspirin (more than 325mg / day) or other salicylates ； 11. those who need continuous prednisone treatment ； 12. those who need antibiotic treatment for infectious diseases ； 13. those with body mass index (bmi) greater than 30 ； 14. people with alcoholism ； 15. people with a history of allergy to lactobacillus and its products or with high sensitive constitution ； 16. researchers who have received other drugs within 3 months before screening ； 17. the people who are researchers thinks it is not suitable to participate in the study.

Keywords: gout hyperuricemia probiotics
adipose tissue pre and post bariatric surgery

Conditions: Obesity

Summary: published data suggest that inflammation and fibrosis of adipose tissue could be factors favoring the development of insulin resistance in obese individuals and that a decrease in the activity of the amp-activity kinase protein (ampk) could lead to these dysfunctions. however, very few data are available in humans. there is also growing interest in persistent organic pollutants (pops) as a cardiometabolic and type 2 diabetes (t2d) risk factor. there is some evidence to suggest that pops directly contribute to lipid metabolism dysfunction and insulin resistance. additionally, pops are stocked in adipose tissue. the accumulation of pops in adipose tissue therefore limits their bioavailability to other organs, thus reducing their systemic toxicity. it has been observed that a large amplitude weight loss leads to a significant increase in pops in the blood. the goal of this project is to identify adipose tissue factors/dysfunctions that contribute to insulin resistance and type 2 diabetes associated with obesity in humans and thus raise avenues for screening and treatment of these metabolic complications. more specifically, the objectives are: * to study the relationship between ampk, fibrosis and inflammation of adipose tissue and their role in the development of insulin resistance and t2d associated with obesity; * to examine the relationship between pops and the cardiometabolic profile.


Eligibility criteria:
inclusion criteria: 1. awaiting bariatric surgery 2. bmi ≥ 35 kg/m2 without cardiometabolic complications or ≥ 30 kg/m2 if presence of type 2 diabetes or hypertension 3. ≥ 18 years old 4. non smoker 5. sedentary (less than 3 hours of regular physical activity per week) exclusion criteria: 1. type 1 diabetes 2. acute event in the last 3 months (myocardial infarction, cerebrovascular hemorrhage or transient cerebral ischemia, unstable angina, peripheral vascular disease, revascularization or angioplasty, recent hospitalization for more than 4 days) 3. infection in the last month (fever, antibiotics treatment) 4. cancer in the last 3 years 5. chronic inflammatory disease 6. pharmacologic treatment (any medication affecting glucose metabolism (except those for diabetes), hypotensive medication unless stable dose for at least 1 month, lipid-lowering medication unless stable dose for at least 1 month) 7. uncontrolled disease of pituitary or thyroid gland 8. bleeding disorders 9. alcohol or drug abuses 10. claustrophobia

Keywords: bariatric surgery persistant organic pollutants type 2 diabetes
analysis of the psychometric properties of kinematic parameters of locomotion measured by inertial measurement units. validation in healthy children and children with cerebral palsy

Conditions: Cerebral Palsy

Summary: cerebral palsy (cp) is currently one of the major causes of disability in children. the presence of various disorders (muscle stiffness, architectural bone defects, spasticity) leads to a number of functional impacts, including severe impairment of mobility, particularly locomotion. locomotion can be assessed using a motion capture system that enables 3-dimensional analysis, in order to help make treatment decisions and quantify them. although these systems are currently considered to be the gold standard, the fact remains that they cause a certain amount of patient fatigue (long set-up times) and that walking is assessed in a laboratory rather than in real life. today, technological advances have brought to the fore other gait analysis devices, such as inertial measurement units (imus). various systems incorporating imus in the feet, for example, respond to these problems of analysing walking in real-life situations. the imus record the movements and orientation of the foot in space; the data is then processed by algorithms to recognise walking steps and calculate the spatio-temporal parameters of locomotion. additional imus positioned on the body can be grafted onto this system to provide a more precise analysis of locomotion, in particular by calculating the movements of the various joints of the lower limb. however, before such devices can be used in a pathological paediatric population, they must be validated in a healthy population. this validation must be conducted using a precise method that has been widely documented in the cosmin recommendations (consensus-based standards for the selection of health measurement instruments). the first stage will assess the safety of the imu devices in a healthy paediatric population, and the validity of the spatio-temporal parameters. if these properties are deemed to be compliant, these same parameters will be assessed in a paediatric population with cerebral palsy in the second stage.


Eligibility criteria:
inclusion criteria: * children who have given their consent and whose legal representatives have given their consent * age between 7 and 17 years, * children able to understand simple commands and instructions. * children living within a maximum radius of 50 km of the investigation site. * child covered by national health insurance. patient group (in addition to those above) * children with proven cerebral palsy resulting in locomotor impairment but able to move around without technical aids (cane, wheelchair). * child covered by national health insurance. exclusion criteria: * children with a condition other than cerebral palsy that affects their ability to walk. * child subject to a measure of legal protection * a child unable to give consent * pregnant, parturient or breast-feeding participant
a double-blind study to evaluate the effect of femarelle® on menopausal on vasomotor symptoms

Conditions: Menopause; Hot Flashes

Summary: the purpose of this study is to test the effects of femarelle ( a plan-derived serm) on hot flushes and quality of life in menopausal women. our hypotheses are that compared to placebo, femarelle reduces the daily number of hot flushes and their severity and also improves the quality of life as measured by validated dairies and questionnaires.

symptomatic menopausal women will be divided to treatment with femarelle or placebo for 12 weeks after two weeks of baseline record. hot flashes daily diary will be recorded daily and a quality of life questionnaire will be filled at the beginning and at completion of the study.

Eligibility criteria:
inclusion criteria: 1. postmenopausal women, i.e 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum fsh levels \> 40 miu/ 2. more than 7 hot flushes per day or over 50 per week at baseline. 3. women should have documentation of a negative screening mammogram (obtained at screening or within 1 year of study enrolment. 4. normal pelvic and breast exams by investigator prior to enrolment. 5. all subjects who have a uterus should have endometrial thickness of less than 5mm in vaginal sonogram exam at randomization. 6. informed consent to participate in the study. exclusion criteria: 1. use of any medication or supplements for menopausal symptoms, such as estrogen/progestin containing drug products, isoflavons, phytoestrogens and serm within a minimum of 8 weeks prior to pre-study screening period. 2. use of ssris, st. john's wort, within a minimum of 8 weeks prior to pre-study screening period. 3. any clinically unstable or uncontrolled renal, hepatic, endocrine, respiratory, hematological, neurological, cardiovascular or cerebrovascular disease that would put the subject at safety risk or mask measure of efficacy 4. evidence or history of vascular disease (such as ischemic heart disease), cerebrovascular accident (such as stroke or transient ischemic attack) or deep vein thrombosis (blood clots), or thromboembolic disorders. 5. personal history of breast cancer 6. abnormal clinically relevant vaginal bleeding 7. any clinically relevant (opinion of investigator) abnormal finding during physical, gynecological and breast examination at screening 8. abnormal, clinically significant results of mammography 9. malignancy with the exception of bcc of the skin 10. known hypersensitivity to gluten, soybeans, soy protein, estrogens and/or progestins 11. history of severe recurrent depression, or severe psychiatric disturbance. untreated or uncontrolled high blood pressure (hypertension) 12. participation in a clinical trial within 30 days prior to screening known substance abuse (alcohol or drug) 13. unable to comply with study protocol

Keywords: menopause hot flashes vasomotor symptoms femarelle soy extract serm
evaluating cardiovascular phenotypes using induced pluripotent stem cells

Conditions: Coronary Artery Disease

Summary: this research is being done to understand how changes in dna may put people at risk for developing coronary artery disease. stem cells will be made using cells from blood and/or skin biopsy samples. we are trying to understand which specific changes in dna negatively impact a person's health.


Eligibility criteria:
inclusion criteria: cases: 1. previously enrolled in the cad module of the genebank at scripps clinic registry 2. eligible to have their blood drawn 3. be reliable, cooperative and willing to comply with all protocol-specified procedures 4. able to understand and grant informed consent controls: 1. previously enrolled in the healthy elderly active longevity (heal) cohort 2. eligible to have their blood drawn 3. be reliable, cooperative and willing to comply with all protocol-specified procedures 4. able to understand and grant informed consent exclusion criteria: 1. unwilling or unable to grant informed consent. 2. have a significant medical condition that in the investigator's opinion may interfere with subject's study participation.
preventing youth soccer injury

Conditions: Injuries; Sports Injury; Sports Injuries in Children

Summary: a study is proposed to test whether adding additional referees to youth soccer matches may reduce the risk of injury to the children playing soccer. publicly-open youth soccer games will be randomly assigned to have either one or three referees and videotaped. the videotaped games will then be watched to record risk-taking behavior by players, referee decisions, and other factors relevant to potential injury.


Eligibility criteria:
inclusion criteria: * unit of measurement was youth soccer teams playing in birmingham, alabama area league exclusion criteria: * teams serving children under age 9 or over age 11

Keywords: youth soccer injury
the effect of tomato ketchup on inflammation

Conditions: Inflammation

Summary: the purpose of this study is to determine the inhibiting effects of a single consumption of tomato ketchup on inflammation which will be induced ex-vivo in human blood.

the consumption of tomatoes and tomato products has been associated with a lower risk of developing cardiovascular disease and some types of cancer. tomatoes and tomato products provide a good source of antioxidants (lipophilic and hydrophilic). the major tomato antioxidants comprise lycopene, α-tocopherol and ascorbic acid. it has been reported that these antioxidants in isolated form exert directly or indirectly anti-inflammatory effects in vitro. studies with tomatoes or tomato products revealed that the observed anti-inflammatory effects could not be caused by the presence of only one antioxidant. it was suggested that these effects were due to the combination of antioxidants. in recent cell culture studies with human endothelial cells we have shown that tomato ketchup exerts significant anti-inflammatory effects, which could be related to the particular composition of antioxidants, i.e. lycopene, ascorbic acid and α-tocopherol. since, however, the relevance of the observed anti-inflammatory effects for humans is entirely unknown, the present pilot study aims to assess the acute effects of a single tomato ketchup consumption on ex vivo elicited inflammation in a small group of healthy volunteers.

Eligibility criteria:
inclusion criteria: * bmi ≤ 30 kg/m2 * age \>18 years exclusion criteria: * occurence of any adverse event, in particular those which require the use of medication that might interfere with the effects and/or the uptake of the investigational products * intolerance of study products * occurence of a serious adverse event * use of supplements, functional foods and/or other products containing tomatoes, vitamins, antioxidants and polyphenolic compounds * use of a medically prescribed diet or slimming diet * vegetarian or vegan lifestyle * excessive alcohol consumption (\< 28 consumptions (approximately 250 g alcohol) per week) * participation in a clinical trial within 4 weeks before the study * non-compliance with the demands of the study

Keywords: inflammation cytokines chemotaxis tomatoes cardiovascular disease
a non-interventional study of sildenafil in the treatment of pulmonary arterial hypertension (pah) in adults from china

Conditions: Pulmonary Arterial Hypertension (PAH)

Summary: this observational study will involve analysis of data collected by the national rare disease registry or medical records .the study will describe outcomes only in pah(pulmonary arterial hypertension) patients treated with sildenafil; there will be no comparison with another treatment group. approximately 100 adults with pah will be recruited in china hospitals this nis(non-interventional study) data will be recorded by a physician in the medical records, during the patients' clinical visits, and in the electronic case report forms (crf).


Eligibility criteria:
inclusion criteria: * at least 18 years of age at study index date; (the index date (i.e., day 1 of the study) is the date when the first sildenafil dose was actually taken, after revatio® is approved by china authority) * a diagnosis of pah with a mean pulmonary artery pressure of ≥25 mmhg and a mean pulmonary capillary wedge pressure of ≤15 mmhg by right heart catheterization; * initiated sildenafil for the treatment of their pah based on treatment suggestion from physician ;(patients who have received sildenafil or are receiving sildenafil are eligible to participate in this study if they met the above inclusion criteria and were ready to start sildenafil (revatio®) for treatment at screening;) * evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. exclusion criteria: * no
effectiveness of diaphragmatic breathing on reflux symptoms in outpatients

Conditions: GERD

Summary: researchers are trying to determine if abdominal breathing exercises can reduce symptoms associated with gerd (gastroesophageal reflux disease).

much like the pelvic floor controls urinary incontinence the "abdominal roof" made of the diaphragm appears to have the ability to control reflux. other studies have had positive results but from extensive training of outpatients. our population comes from ambulatory outpatients from family medicine at mcj. after consent they fill out a reflux disease questionnaire (rdq) a valid instrument for measuring symptoms of reflux. subjects are educated on the basic concept of the study and then instructed in isolated diaphragm contraction breathing. once they are proficient they are asked to continue this program 3 x 10 repetitions, 3 times per day supplemented by 10 more repetitions after each meal to reduce post prandial symptoms. follow up is done at 1, 3 and 6 months and includes reassessment via the rdq and an assessment of estimated volume of exercise compliance.

Eligibility criteria:
inclusion criteria: * adults with complaints of gerd, reflux, and/or heartburn symptoms exclusion criteria: * none

Keywords: reflux heartburn
a study of et-02 in patients with relapsed or refractory b-cell malignancy(nhl/all)

Conditions: Relapsed or Refractory B-cell Malignancy(NHL/ALL)

Summary: the purpose of this study is to evaluate the safety and efficacy of cd19-ucart in patients with r/r b-cell hematological malignancies.


Eligibility criteria:
inclusion criteria: 1. patients volunteer to participate in the study and sign the icf; 2. male or female aged≥18 years old； 3. patient with relapsed or refractory cd19 positive b-all ornhl，as evidenced by 2 or more lines of prior therapy ; 4. estimated life expectancy≥12 weeks ; 5. ecog performance status ≤1; 6. adequate organ function. exclusion criteria: 1. patients with graft-versus-host disease (gvhd) or requiring immunosuppressive therapy； 2. history of central nervous system (cns) involvement by malignancy； 3. women who are pregnant or breastfeeding； 4. any situations that may increase the risk of patients or interfere with the results of study，which judged by investigator.
lengthening temporalis myoplasty and improvement of primary swallowing disorders in facial paralysis

Conditions: Peripheral Facial Paralysis

Summary: the facial paralysis is a frequent disease causing important functionals swallowing dysfunctions. the purpose of our study was to evaluate the improvement of the swallowing disorders after surgery by lengthening temporalis myoplasty (ltm) in the facial paralysis. this prospective study has realised on the following of patients affected by facial paralysis treated by ltm. self-administered questionnaires and clinics tests had realized to analyze three components oh the oral phase of the swallowing ( drooling, mastication and handicap). the evaluations was realized before the surgery and at 3 and 6 months after .


Eligibility criteria:
inclusion criteria: * chronic peripheral facial paralysis * freyss score inferior at 15 * benefiting of a lengthening temporalis myoplasty exclusion criteria: * malformative syndrome * other swallowing trouble * psychiatric trouble * opposed at this study
impact of botox treatment into the upper one third of the face an area on mood and self -appearance satisfaction

Conditions: Mood

Summary: botox treatment into the upper one third of the face (glabella, forehead lines and/or lateral canthal lines) to analyze mood and self -appearance satisfaction in a post covid period on non-naïve botox patients

a historical period that will never happen again provides us a unique opportunity to evaluate the impact botox cosmetic has on the mood and self appearance satisfaction after a societal crisis such as the covid19 pandemic. many regular users of botox cosmetic will have exceeded their normal treatment interval and their glabellar wrinkles will likely have returned to baseline. many will want to get treated as soon as stay at home orders are rescinded and clinics are permitted to open back up. it would not be surprising that these patients also are experiencing a decrease in their mood secondary to weeks of social isolating and distancing. many can expect to have a rebound elevation in their happiness and overall mood following the modified return to normalcy. botox cosmetic has been studied as a mood elevating drug by reducing the animation of a glabellar furrow via the facial feedback mechanism hypothesis. this has been shown in patients who are not diagnosed with a major depressive disorder. following a natural disaster, does the administration of botox cosmetic, in patients who are frequent botox cosmetic users, synergistically amplify the elevation in mood beyond what would be achieved had they not had their botox cosmetic treatment. perhaps regular botox cosmetic users have a secondary gain desire for botox cosmetic beyond wrinkle reduction but also as a mood elevator.

Eligibility criteria:
inclusion criteria: * males and females between the ages of 18-75 * subjects will be non-naive botox users with a glabellar wrinkle severity score of 2 or 3 who are at least 20 weeks from their last botox cosmetic treatment * subjects that understand the purpose and aspects of the study, freely sign the consent and complete the required treatment and follow up visits. exclusion criteria: * males and females below the age of 18 * subjects that received neuromodulator injections to the glabella region in the last 20 weeks * subjects who do not meet a 2-3 wrinkle severity score in the glabellar region * subjects who have received other invasive or semi invasive cosmetic forehead or glabellar treatments * subjects who have had a change in antidepressant or anti- anxiety medication in last 6 weeks * subjects with severe depression, bipolar disorder, pregnant, * subjects who are pregnant, attempting to get pregnant, or breast feeding * subjects with a known allergy or sensitivity to any component of the study ingredients. * subjects that do not understand the purpose and aspects of the study, do not sign the consent and do not complete the required treatment and follow up visit will also be excluded.